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The differentiation of myosin into the respective heavy chain isoforms has
shown a correlation with high mechanical stress. Aortic valve myosin expression
has been reported; however, the characterization of the pressure response has
yet to be fully developed. Thus, a cyclic pressure bioreactor was developed to
elucidate the α/β-myosin heavy chain (MHC) expression in aortic valve leaflets
subject to physiological and pathological transvalvular pressure loads.

The

pressure bioreactor achieved the desired pressure modulation via LabVIEW
controlled solenoid valves. Results showed α/β-MHC expression on the fibrosal
endothelium and minimal dispersal in the subendothelium, indicating the
presence of smooth muscle cells. Endothelial layer denudation was evident with
time progression while protein expression was limited to sites of excision or
injury, indicating a causal relationship with high shear stress. In conclusion, α/β-

MHC expression is limited by endothelium detachment and lack of smooth
muscle cells, possibly on account of insufficient mechanical stimuli.
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CHAPTER I
INTRODUCTION
The aortic valve is located between the left ventricle and the aorta, and
allows unidirectional blood flow, preventing backflow into the ventricle. The valve
withstands a harsh, dynamic environment that is constantly exposed to several
different types of mechanical stresses, including shear, bending, tension, and
compression. Aortic valve disease (AVD) is a form of cardiovascular disease
that results in either restricted blood flow across the valve, or regurgitation of
blood into the left ventricle. Symptoms associated with AVD include shortness of
breath, angina, dizziness, heart palpitation, etc., which are symptoms similar to
several other cardiovascular diseases; therefore, AVD is difficult to detect until
valve replacement and surgical intervention are necessary. Current treatment
options include the use of mechanical or prosthetic valves, capable of functioning
effectively for approximately ten years. While suitable for adults, children with
malfunctioning valves must undergo repeat operations as artificial valves are
unable to grow with the child. Improved understanding of valve mechanobiology
in response to pressure would help elucidate the mechanisms of valve
pathogenesis.

In turn, this could help in the development of non-invasive

therapies such as pharmaceutical prevention. This thesis aims to explore the
1

aortic valve’s response to cyclic transvalvular pressure, with respect to α/βmyosin heavy chain expression, to give further insight into the appearance of
muscle fibers in a normally passive valve.

Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death and accounts
for approximately 30% of all deaths worldwide.

In 2005, an estimated 17.5

million people died from cardiovascular diseases, which include coronary heart
disease, hypertension, aortic valve disease (AVD), rheumatic heart disease,
congenital heart disease, and heart failure.

1

In the United States today,

approximately 80,700,000 adults are diagnosed with one or more types of CVD.
Every 37 seconds an American dies of CVD; this amounts to almost 2,400
deaths each day.

2

Furthermore, an estimated $448.5 billion will be spent on the

direct and indirect costs of CVD in the U.S. in 2008. 2
Several CVDs are correlated with different aortic valve pathologies, due to
the importance of maintaining physiological valve contraction and subsequent
ventricular ejection. Aortic valve disease may be caused by congenital valve
disease, infective endocarditis, rheumatic fever, fibro-calcific degeneration, or
possibly dilation of the valve annulus, amongst others.

2-5

In 2002, over 12,500

American deaths were directly attributed to aortic valve disease. AVD was also
an underlying factor in an additional 26,336 deaths and 48,000 hospital
discharges. 6

2

Aortic Valve Physiology
Aortic valve leaflets are composed of interstitial cells suspended within an
extracellular matrix and are lined with an endothelial cell monolayer.

The

extracellular matrix (ECM) within the valve is composed of hyaluronic acid,
proteoglycans, glycosaminoglycans, and collagen fibrils, which bear the majority
of the tensile and compressive forces acting on the leaflet.

7,8

The collagenous

tissue of the valve is composed of ~60-70% water by weight, which is tightly
bound to the fibrous tissue network and contributes to valve incompressibility.
Leaflets exhibit viscoelastic behavior due to the elastic response to loading from
the solid ECM components, and a viscous response attributed to the fluid
components. The aortic valve is composed of three layers: the fibrosa, located
on the aortic surface of the valve; the spongiosa, the middle layer; and
ventricularis, found on the ventricular side of the valve. A schematic diagram of
the organization of the structural components of an aortic valve leaflet can be
seen in Figure 1, whereas actual collagen composition can be seen via Masson’s
trichrome stain in Figure 2. The structure of each layer plays a critical role in the
maintenance and operation of the valve. 9-12
Aortic

valve

leaflets

exhibit

significant

directionality

of

structural

components. The specific alignment of fibrous components lends the valve its
highly anisotropic strain response.

7,13,14

The orientation of aortic valve

components can be characterized as either radially or circumferentially aligned
and is depicted in Figure 3. The radial direction describes the alignment along the
3

leaflet from the aortic root attachment extending out toward the tricuspid nexus of
the aortic valve. The circumferential direction indicates that the alignment follows
the imaginary perimeter of the valve annulus ring and decreasing concentric
circles that span the three leaflets.
The mechanical properties of the aortic valve are supplied by only the
fibrosa and ventricularis layers. Collagen and elastin are the principal structural
components of heart valves. The fibrosa is composed mainly of collagen and
constitutes 30-40% of the total thickness of the valve.

15

The fibrosal collagen,

organized into fibers and bundles, is predominantly circumferentially aligned.
Collagen within the ventricularis is less prevalent and more disordered, as
compared to collagen within the fibrosa. The ventricularis combines collagen
with elastin fibers, which are organized into a mesh, or continuous sheet that
spans the entirety of the layer.

16

Elastin located within the fibrosa is more

sporadic, manifesting in large tubes of loose mesh that surround the much larger
collagen bundles, aligned circumferentially.

4

Figure 1: Schematic diagram of the trilayer configuration of an aortic valve,
illustrating the elastin sheets within the ventricularis, GAG-rich matrix
comprising the spongiosa, and the collagen fibers contained within the
fibrosa.

5

A

B
Figure 2: Masson’s trichrome stain of collagen (blue) within the (A) fibrosa and
(B) ventricularis
6

Figure 3:

Aerial view of aortic valve indicating alignment conventions in the
radial (R) and circumferential (C) direction

Aortic Valve Cellular Biology
The mature aortic valve functions through complex interactions between
two distinct cell types, the endothelial cells and the interstitial cells. To fully
appreciate the individual cell phenotypes, a brief overview of the origins of the
cell types and the valve maturation process, known as valvulogenesis, is needed.
The embryonic heart begins as a primitive bi-layered tube of adjacent
endocardial and myocardial monolayers encompassing an interstitial matrix
known as cardiac jelly. As the heart develops further, the cells and jelly that
cover the future atrioventricular canal and outflow tract begin to distend outward.
The resulting protrusions are referred to as cardiac cushions. 17 A process known
as the endothelial to mesenchymal transformation, or EMT, occurs which results
7

in delamination and remodeling events. While the atrioventricular tract cushions
eventually form the mitral and tricuspid valves, the aortic valve forms in the
developmental outflow tract. The exact pathways that lead to the differentiation
are not currently known, although intense research has been focused on the role
of growth factors, endothelial nitric oxide synthase, and bone morphogenic
proteins, matrix metalloproteases, periostin, etc.

18-22

The end stage functional

aortic valve leaftlet has recently been shown to have cell populations with an
endothelial origin.

23,24

A key tenet of aortic valve cellular biology is the plasticity

of the cell phenotypes, which allows for extensive remodeling essential to valve
durability.

Endothelial Cells
The aortic valve endothelial cell is an extremely mechanosensitive cell
type.

The aortic valvular endothelial cell senses a variety of forces in vivo,

including fluid shear stress due to the demanding pulsatile hemodynamic
environment, and cyclic strain with particular regard to diastolic transvalvular
pressure. Endothelial cells have a cobblestone-like morphology and readily form
monolayers on both sides of the valve leaflet.

The endothelial cell is

circumferentially aligned on both sides of the aortic valve.

25

A key function of the

endothelial layer is to sense environmental forces and transmit biochemical
signals to the interstitial cells. 26 Aortic valve sclerosis has been linked to an initial
event of endothelial layer removal, or denudation. A pro-inflammatory reaction
occurs, which allows endothelial cells to produce adhesion molecules to bind
8

circulating leukocytes and allow migration into the sub-endothelial layer.

27

Current research is being conducted to further elucidate the mechanobiology of
the valvular endothelial cell.
Valvular endothelial cells are a distinct cell population from the vascular
endothelial cell. J. Butcher observed the rearrangement of focal adhesions to
regulate the directional response to shear stress. The vascular endothelial cell
aligns parallel to the direction of flow, whereas the valvular endothelial cell aligns
perpendicularly to the direction of flow.

28,29

It is not currently known whether the

fibrosal endothelial cell is a distinct phenotype from the ventricularis endothelial
cell, although gene expression profiles have indicated they may be different.

30

The response of endothelial cells to other mechanical stimuli, such as stretch and
pressure, are currently under investigation.

Interstitial Cells
As previously stated, interstitial cells respond to mechanical stimuli as well
as biochemical signals transmitted from endothelial cells. Studies have shown
that interstitial cells are responsible for repairing and remodeling the valve
leaflets by increased cell proliferation, migration, and matrix synthesis or
degradation, depending on the biochemical signaling or intensity of mechanical
stimuli.

31

Three distinct phenotypes of interstitial cells have been characterized

in the mature native valve: fibroblasts, myofibroblasts, and smooth muscle cells.
32

About 80% of interstitial cells in normal, non-collagen synthesizing cells have

been classified as quiescent fibroblasts and are characterized by vimentin
9

expression, but these fibroblasts do not express α-smooth muscle actin, or nonmuscle myosin heavy chain.

33,34

However, while actively remodeling the valve,

fibroblasts synthesize collagen, elastin, proteoglycans, growth factors, cytokines,
fibronectin, chemokines, and matrix metalloproteinases (MMPs).

Valvular

metalloproteinases perform extracellular matrix remodeling and control growth
factor production.

35

Fibroblasts have been shown to differentiate into

myofibroblasts when stimulated by transforming growth factor-β, as a result of
increased contractility and up-regulation of extracellular protein production in
transdifferentiated cells. 36
The dynamic, myofibroblast phenotype has been shown to differentiate
between fibroblast and smooth muscle cell, and is also suggested to be involved
in cellular contraction, proliferation, and migration.

Myofibroblasts display

characteristics of both fibroblasts and smooth muscle cells by expressing
contractile properties, secreting extracellular matrix, and containing both muscle
and non-muscle regulatory and structural proteins.

37,38

Myofibroblasts are

typically characterized by antibody reactions to microfilaments (α-smooth muscle
actin) and intermediate filaments (vimentin and desmin). 9
Smooth muscle cells, the third interstitial cell phenotype, have been found
either singly or arranged in thin bundles and are also thought to be involved in
valvular contraction.

39

Smooth muscle cells are distinguished by the expression

of α/β-myosin heavy chain, SM1, representing differentiated smooth muscle cells;
and by the expression of α-myosin heavy chain, SM2, representing mature
10

smooth muscle cells.

Rabkin et al. has shown that the phenotypic state of

valvular interstitial cells is related to the remodeling demand of the tissue, and
has correlated cellular contractility to biosynthetic activity.

40

To support this

claim, Merryman et al. has shown a strong relationship between smooth muscle
actin and HSP47, a collagen biosynthetic protein. The results of Merryman’s
study imply that homeostasis is continually maintained by valve remodeling via
collagen production and phenotypic differentiation from fibroblasts into
myofibroblasts and smooth muscle cells. 41
As previously stated, several different types of contractile proteins are
found within the aortic valve. Various antibodies for contractile proteins, such as
vimentin, α-actin, and myosin, have been used to characterize valvular interstitial
cells into fibroblasts, myofibroblasts, and smooth muscle cells. Table 1 illustrates
interstitial cell reaction to contractile antibodies. Endothelial cells stain heavily for
vimentin; however, no studies have shown positive staining for desmin or αsmooth muscle actin. Myosin has been found within the endothelial layer, but the
exact form of myosin has yet to be classified. 42
Table 1: Interstitial cell classification via contractile protein antigen reaction 9
Antibody

Filament System

Fibroblasts Myofibroblasts SMC

Vimentin Intermediate-mesenchymal

+

+

+/-

α-Actin

Microfilament-actin

-

+/-

+

SM1

α/β-Myosin heavy chain

-

+/-

+

SM2

α-Myosin heavy chain

-

+/-

+

11

Vimentin is an intermediate filament protein and is the first protein to be
expressed during cell differentiation. During valvulogenesis, vimentin has been
shown to align circumferentially on the ventricularis, whereas it appears as a
network on the fibrosa.

43

Additionally, valvular endothelial cells have a higher

volume density of vimentin as compared to valvular interstitial cells, suggesting
an accommodative mechanism involving such filaments. 44 Although classified as
a cytoskeletal protein, vimentin has also proven available for autoantibody
binding and T-cell recognition; therefore, vimentin may be involved in the
inflammation of the heart as with rheumatic heart disease. 45
α-Smooth muscle actin (α-SMA) is a microfilament found within cells that
require migration.

Interstitial cell fibroblasts are quiescent; however, when

cellular migration is necessary, they differentiate into myofibroblasts (and
sometimes smooth muscle cells) and acquire α-SMA for locomotion.
reason, α-SMA is often used as a myofibroblast marker.

34

For this

Migration may be

required for tonus in response to mechanical stimuli, or possibly as an immune
response to injury. During embryonic development, α-SMA is scarce on both
faces of the valve cusps but is suspected to increase after the initiation of
interstitial cell differentiation. 43
Myosin heavy chain (MHC) is found as three different dimers: (1) two αMHC form a homodimer; (2) one α- and one β-MHC form a heterodimer; and (3)
two β-MHC form a homodimer.

46-48

These dimers are characterized by Ca²12

activated ATPase activity and mobility, with α-MHC having the most contractility
and β-MHC having the least.

48

β-MHC and α-MHC are characterized as slow-

and fast-twitch muscle fibers, respectively.

α/β-MHCs, consequently, show

characteristics of both α-MHC and β-MHCs and are thus believed to be an
intermediate form of MHC. β-MHCs are exclusively found in embryonic heart
development and are eventually completely replaced by α-MHCs in an adult.

47

Studies have shown adult α-MHC in the heart redifferentiates into β-MHC as a
result of increases in mechanical stimuli for extended periods of time, as with
hypertrophy; however, as mechanical stimuli decrease in intensity, β-MHC
reverts to α-MHC.

47,49,50

Interestingly, research shows no α-MHC is present in

the end-stage failing human heart, which may suggest full redifferentiation to
developmental slow-twitch β-MHC unable to meet functioning heart contraction.
51

Also,

weakened,

enlarged

hearts,

a

condition

known

as

dilated

cardiomyopathy, is also associated with increased β-MHC and a decreased
contractility. 52 To date, valve research has found α/β-MHC and α-MHC in smooth
muscle cells within remodeling valves; however, β-MHC expression within heart
valves has been ignored and should be investigated further.

Aortic Valve Biomechanics
Located between the left ventricle and aorta, the aortic valve allows blood
passage in systole, and prevents retrograde blood flow during diastole.

The

three valve cusps open in the systolic phase with maximum flexibility and close in
the diastolic phase with necessary tissue strength. The aortic valve changes
13

geometry throughout the cardiac cycle in response to loading. The cusps rotate
when opening and closing, which causes a bending stress along the line of
coaptation, located radially from the area of leaflet attachment.

53

The location of

the line of coaptation is illustrated in Figure 4. Collagen within the fibrosa layer
allows for maximum leaflet coaptation during closure and plays a vital role in
maintaining valve durability. During systole, collagen fibers in the fibrosa layer
become folded and compacted to allow for maximum orifice area for blood flow.
Alternatively, during diastole when the valve is closed and under tensile stress,
the collagen fibers are uncrimped and reoriented to withstand high mechanical
stress. 9,54

Line of Coaptation

Figure 4: Illustration of the line of coaptation

The spongiosa layer contains hydrophilic proteoglycans which are
responsible for cushioning and absorbing stress.
14

9,54

The elastin in the

ventricularis layer serves to maintain the circumferential alignment and proper
spacing of collagen bundles when the valve is open during systole.

Elastin

provides the recoil necessary to properly align the fibers when the leaflets begin
to close and extend out toward the line of coaptation.

9,54,55

Vesely and

Noseworthy found that the amounts of collagen within the radially-oriented
ventricularis and fibrosa are similar, but the fibrosa has higher radial extensibility
due to its highly folded configuration. 55,56 Aortic leaflets under tensile stress have
shown a significant difference in stiffness in the circumferential direction as
compared to the radial direction.

57

As a result, circumferentially aligned collagen

fibers in tension prevent separation of radially aligned collagen fibers, illustrated
in Figure 5. 58

Radial

R
C

Biaxial
Figure 5:

Demonstration of collagen alignment when radially and biaxially
stretched 58

15

The transvalvular pressure gradient dictates the opening and closing of the
aortic valve.

The valve is closed until ventricular pressure surpasses aortic

pressure, at which point the aortic valve opens and releases the pressure across
the valve. Pressure levels in the aorta vary from 80-120mmHg, affecting the
fibrosa layer of the aortic valve; whereas, pressure levels in the left ventricle vary
from 0-120mmHg, affecting the ventricularis layer. For this reason, the valve is
constantly exposed to transvalvular pressure gradients ranging from zero when
the valve is open, up to 80mmHg when the valve is closed in normal conditions.
Studies show that valvular cells from the left side of the heart are stiffer when
compared to valvular cells from the right side of the heart, which correlates with
the higher transvalvular pressure experienced by the left side (when compared to
the right side) of the heart.

41

In addition, α-smooth muscle actin content and

collagen biosynthesis were also correlated to cellular stiffness and transvalvular
pressure. Elevated pressures result in increased bending stresses and leaflet
strains, which are also correlated to collagen biosynthesis.

41

Thubrikar et al.

modeled in vivo leaflet stress as a function of transvalvular pressure by
considering bending and stretching independently:

⎛ T ⎞
⎛ PR ⎞
Stress = ⎜
⎟
⎟ ± E⎜
⎝ 2R ⎠
⎝ T ⎠
where P represents transvalvular pressure, R denotes the radius of the leaflet, T
is valve thickness, and E is the leaflet modulus of elasticity.

The bending

stresses affecting the valve are either tensile (+) or compressive (-), depending
16

on the side of the leaflet.

13

Diastolic leaflet strain,

ε , as a result of transvalvular
D

pressure can be calculated experimentally, using the following equation:

ε =ℓ - ℓ / ℓ
D

where

ℓ2

2

1

1

represents the radial length of the leaflet at the highest transvalvular

pressure gradient, and

ℓ1

corresponds to radial leaflet length at a 60mmHg

pressure gradient. Figure 6 demonstrates how diastolic strain can be calculated
experimentally.

17

Figure 6:

Typical plot of leaflet length vs. pressure gradient across the leaflet in
vivo in a single dog. The circles represent measured leaflet length
and measured pressure gradient in diastole. The bars represent
measured leaflet length and assumed pressure gradient of 0 to
10mmHg in systole. The lengths ℓ0, ℓ, ℓ1, and ℓ2 correspond to the
gradients of 0, 10, 60, and 200mmHg, respectively. Diastolic strain is
represented by εD, whereas systolic strain is represented by εS. 58

Research has shown calcific lesions in diseased valves tend to occur in
areas of high mechanical stress as a result of endothelial disruption or interstitial
matrix damage.

59-61

Moreover, calcified sclerotic lesions typically occur in the

subendothelial space on the aortic side of the valve (fibrosa) in regions of low
shear stress with oscillatory flow.

62,63

Calcific deposits are also common along
18

the line of coaptation as a result of high bending stress.

61

These studies prove

that mechanical stresses play a significant role in valvular pathogenesis. Further
investigation of the biological response to force will broaden the working
knowledge of heart valve biomechanics and associated diseases.

Hypertension
Elevated blood pressure alters the mechanical environment of the aortic
valve and has been linked to aortic valve disease. According to the American
Heart Association, nearly one in three adults in the United States is diagnosed
with high blood pressure.

2,53

Hypertension is a risk factor for several

cardiovascular disorders, including heart failure, stroke, atherosclerosis,
intracranial hemorrhage, and dissecting aortic aneurysms. In 2004, high blood
pressure total mention mortality was around 300,000 which is a 56.1% increase
in deaths since 1994.

2,53

Hypertension is defined as a persistent elevation of

blood pressure and is classified by the criteria shown in Table 2. 64
Table 2: Classification of blood pressure
Diastolic (mmHg)

Systolic (mmHg)

Normotensive

< 80

<120

High Blood Pressure

80-89

120-139

Stage I

90-99

140-159

Stage II

100-109

160-179

Stage III

110-119

180-209

Stage IV

>120

>210
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Hypertension may be a result of abnormal functioning of the kidneys,
heart, vasculature, or nervous system, improper diet, genetics, or a combination
thereof.

65-67

For example, excessive renin secretion by the kidneys and the

associated increase in water and sodium retention can elevate blood pressure.
When hypertension is a result of another disorder (i.e. kidney disease), it is
referred to as secondary hypertension; whereas, when the exact cause is
unknown, it is referred to as primary hypertension. High blood pressure is either
induced by, or causes, functional and morphological changes in the vasculature,
such as thickening of the arterial wall and altered stiffness and contractile
response. Similar changes in thickness, stiffness, and contractility have been
observed in aortic valve leaflets diagnosed with AVD; therefore, it is particularly
important to study the biomechanics of hypertension with respect to the aortic
valve. 4,5,41,61,68-73

Aortic Valve Disease
Irregularities of the aortic valve can lead to aortic valve diseases, such as
valve stenosis and/or regurgitation. To effectively manage aortic valve disease,
traditional treatment algorithms should be followed:

early gross diagnosis,

noninvasive imaging, catheterization or angiography, and medical treatment until
symptoms progress and indicate surgery is necessary.

4

Left untreated, aortic

valve disease can result in heart failure, infection, and sudden death.

20

Aortic Stenosis
The term aortic stenosis refers to the narrowing of the aortic valve opening
during systole.

Two general types of aortic stenosis exist.

The first is a

congenital abnormality of the valve and is often detected in childhood.

The

second is caused by progressive calcium and scar tissue buildup. Scar tissue
and calcium can collect on an abnormal congenital valve from damage due to
rheumatic fever, or on the aortic valve leaflets gradually with age. The incidence
of major aortic stenosis causes the left ventricle muscle to thicken in order to
overcome the stress of the obstruction. The resulting thick muscle becomes stiff
and causes a high pressure in the left ventricle when it fills with blood. This
pressure is consequently transmitted to the lungs and generally causes
shortness of breath in patients, and may potentially cause additional damage to
the aortic valve. Other symptoms that accompany severe aortic stenosis include
angina, dizziness, and possible sudden death. 74

Aortic Regurgitation
The term aortic regurgitation refers to leakage in the aortic valve allowing
a backwards flow of blood into the left ventricle during diastole. This form of
valve disease can be caused by structural abnormalities of the valve.
Enlargement of the aorta stretches the valve leaflets and produces aortic
regurgitation. Acute onset of aortic regurgitation can occur as a result of either
an infection of the aortic valve or a tear in the aorta. Chronic aortic regurgitation
is often present for some time before any symptoms arise. The regurgitation
21

causes a large volume of blood to flow backward into the left ventricle. The
ventricle compensates for the increase in blood volume by enlarging the cavity
and increasing the thickness of the cardiac muscle.

74

Left ventricular

compensation allows the heart to pump typical blood volume required by the
body, plus additional blood that flows backwards into the ventricle. Symptoms
that accompany severe aortic regurgitation are shortness of breath and chest
pain. Long-term untreated aortic regurgitation results in irreversible damage to
the muscle tissue of the left ventricle; in these cases an aortic valve replacement
is necessary. 75

Current Treatment Options
Often times, valvular pathologies slowly progress, making them difficult to
diagnosis until surgical intervention is necessary.
replacement surgeries are performed each year.

2

Over 100,000 valve

Currently, several different

treatment options, including bioprosthetic and mechanical aortic valves, are used
to replace damaged or diseased aortic valves. Each replacement option has
advantages and drawbacks; therefore, surgeons must choose the appropriate
valve replacement to suit the patient’s physiological needs and lifestyle.

Bioprosthetic Aortic Valves
Several different types of bioprosthetic aortic valves exist, including
allograft and xenograft prosthesis, as shown in Figure 7. The major drawback of
bioprosthetic aortic valve replacements is their tendency to wear out over time.
22

In older, less active adults, the bioprosthetic valve can operate effectively for 20
years or more; however, younger, active patients would require a secondary
valve replacement surgery after approximately 10 years, due to deterioration of
the valve and growth of the patient.

76-82

Nonviable allograft aortic valves are

obtained from cadavers at autopsy, sterilized by incubation with low-dose
antibiotics, and can be stored at 4˚C for weeks. Since the replacements are
nonviable, they are unable to repair and remodel the valvular tissue in response
to injury or high mechanical stress; therefore, they wear out quickly.
Alternatively, viable allograft valves are collected from transplant donors and are
cryopreserved within two hours of collection. Cryopreserved allograft valves are
replaced less frequently than refrigerated valves because cellular activity slows
deterioration.

83,84

Allograft valves are preferred over xenograft valves because

they are structurally identical to the valve to be replaced; however, the supply is
very limited. Porcine xenograft aortic valve replacements are similar in structure
and hemodynamics to human aortic valves and are readily available, making
them an ideal substitute for allograft valves. However, porcine valves must be
fixed with glutaraldehyde for non-immunogenic purposes, a process that can lead
to calcification.

Also, xenograft aortic valves, similar to allograft valves, lack

cellular activity and tend to degenerate due to mechanical wear. 85-87
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B

A
Figure 7: (A) Allograft (B) Porcine xenograft bioprosthetic valve
(chelationtherapyonline.com)

Mechanical Aortic Valves
Mechanical valves are sometimes used as an alternative to bioprosthetic
valves due to their durability; however, high shear stress across the implant
activates platelets, causing thrombosis formation. 88 As a result, the patient would
require lifelong anticoagulation therapy.

Ideally, mechanical valves would

prevent regurgitation while minimizing shear stress and turbulent blood flow.

89-91

Similar to bioprosthetic valves, mechanical valves are best suited for mature
adults, and patients typically require replacement surgery after approximately 20
years.

76,77,79,88,89

Several different types of mechanical valve replacements exist,

including caged ball, tilting disk, and bileaflet valves, all shown in Figure 8.

88,92

Caged ball valves oscillate a rubber ball within a cobalt-chromium alloy cage to
regulate blood flow between the left ventricle and the aorta via changes in
pressure gradients.

The drawback to using caged ball valves is that they

produce a higher amount of turbulent flow compared to replacement valves that
24

utilize rotating disks.

93

Tilting disk valves use a single, circular disk held by wire-

like arms, whereas bileaflet valves employ two semicircular leaflets connected by
hinges. Typically, these disks are made of stainless steel, titanium, silicone, or
pyrolytic carbon and are sewn into the patient via double velour, knitted polyester
cuff.

94

Having been implanted into around 600,000 patients, bileaflet valves are

the most popular mechanical valve as compared to the tilting disk valve and balland-cage valve, having 360,000 and 200,000 implantations, respectively. 93

A

B

C

Figure 8: Mechanical valves (A) Starr-Edwards caged ball (baxter.com) (B) Sorin
Medical tilting disk (sorin.com) (C) St. Jude’s bileaflet (sjm.com)

Tissue Engineered Aortic Valves
Due to the limitations of bioprosthetic and mechanical valves, engineers
are currently striving to tissue engineer a replacement aortic valve that is nonthrombogenic, able to withstand dynamic mechanical stress, and remodel and
grow with the patient. To do so, engineers have attempted to create a viable
tissue that is able to respond to the body’s needs and develop along with the
patient.

95

Recreation of aortic valve tissue function requires researchers to first
25

understand the aortic valve response to stimuli. Study of aortic valve biology and
mechanics have lead to the development of two fundamental strategies,
including biodegradable polymeric scaffolds, and non-degrading biological matrix
scaffolds.
Biodegradable polymers repopulated with autologous cell types are the
most widely used strategy. Both separately and in combination, poly(lactic-coglycolide) (PGLA), poly-3-hydroxyoctanoate (PHO), and polyhydroxyalkanoate
(PHA) have been used as biodegradable polymers in valve design due to their
mechanical properties, melting temperatures, biocompatibility, and degradation
time.

96

After implantation, the polymer begins to slowly degrade and the active

cell types within the polymer generate biological matrix to compensate for
polymer degradation.

Essentially, new, viable valve tissue is created in the

absence of the polymer scaffold; however, this strategy has failed to produce
satisfying results. Polymer degradation via hydrolysis alters pH of the valve’s
biochemical environment, leading to undesired cell death and differentiation,
offering a possible explanation of failure.

97,98

An additional source of malfunction

may be due to the use of vascular autologous cells rather than valvular cells,
which have shown to have different phenotypes and mechanical behavior. 25
The alternative strategy, biological matrix scaffold valve replacement, is
less developed than the previously discussed valve design. Collagen, fibrin, and
chitosan have been used as possible valve matrix materials, both in combination
and independently.

99-101

The advantages of using solely biological material for
26

valvular scaffolds is the wide availability of these materials from xenogenic
sources, the ability to accommodate cellular growth, ease of processing, and lack
of cytotoxic degradation by-products.

Although advantageous, the use of

biological matrix scaffolds has yet to produce a material capable of withstanding
native valve’s harsh, dynamic, mechanical environment.

102

Bioprosthetic and

mechanical valves will continue to be used as valve replacements; however,
scientists refuse to surrender to this challenge and will continue to explore
different bioengineering alternatives and techniques until a suitable tissue
engineered valve replacement is created. In the meantime, further research is
necessary to fully understand the origin and progression of aortic valve disease.
The ultimate goal is to avoid valve replacement surgery by early intervention and
the development of non-invasive therapy, thus improving the patient’s quality of
life.

Objective of the Study
The objective of this study was to investigate a change in α/β-myosin heavy
chain expression, if any, of aortic heart valve leaflets due to varying magnitudes
of transvalvular pressure. In order to achieve this objective, two goals must be
accomplished: (1) a cyclic transvalvular pressure bioreactor must be created,
and (2) myosin expression must be evaluated after exposing aortic valve leaflets
to varying levels of pressure.

27

Scope and Limitations of the Study
This study concentrates on the response of aortic valve leaflets exposed
exclusively to cyclic transvalvular pressure, independent of other mechanical and
biochemical stimuli. Rather than studying how the valve responds to multiple
forces simultaneously, the bioreactor allows researchers to focus on the direct
effects of pressure to valve mechanobiology. As previously stated, aortic valve
disease is associated with high transvalvular pressure and diastolic strain across
the aortic valve leaflet; therefore, the bioreactor will only be required to cycle
between, at least, 60mmHg and 80mmHg, for physiological conditions, and
60mmHg to 100mmHg for pathological conditions.
pressure has little to no effect on leaflet strain.

58

Systolic transvalvular

Also, Shin et al. demonstrated

that pressure magnitudes between 20-60mmHg did not cause significant
changes in endothelial barrier function; therefore, systolic transvalvular pressure
will be neglected.

103

Preliminary studies of aortic valve mechanobiology as a

result of transvalvular pressure will focus on changes in cellular phenotype with
respect to α/β-myosin heavy chain.

Healthy valves are passive by nature,

opening and closing as a result of pressure gradients rather than muscle
contraction; however, this study will elucidate the cellular response of
myofibroblast differentiation from fibroblasts to smooth muscle cells observed
during valve remodeling and disease. 9,34,40
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CHAPTER II
DESIGN OF A CYCLIC PRESSURE BIOREACTOR

Brief History of Heart Valve Bioreactors
To investigate cellular and tissue responses to mechanical stimuli,
bioreactors are used to simulate the valve’s biomechanical and biochemical
environments.

104-107

Ex vivo and in vitro experimental models provide a cost

effective alternative to in vivo animal models, due to the high costs of purchasing,
housing, feeding, and providing care for the animals used in testing. Bioreactors
are typically used for regulatory clearance tests on prospective valve
replacement options prior to FDA approval.

108

They are also used for

mechanically conditioning tissue engineered valve constructs due to the
mechanosensitivity of valvular cells.

104

However, the long term goal of valvular

study within a bioreactor is to predict tissue structure and function by studying
cell, scaffold, media, and environmental conditions, thus providing a rational
basis for future tissue engineering design.

108

Previously, bioreactors have been

constructed to study the valvular response to both tension and shear stress.
109,110

Flexural stress has also been simulated in a laboratory setting; however,

the majority of bioreactors mimic the pulsatile blood flow across the valve leaflet,
thereby testing the valvular response to both pressure and shear stress. 107,111-115
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Xing et al. created a bioreactor to study the effects of cyclic pressure with no
other mechanical interference; however, Xing cycled pressure between 80mmHg
and 120mmHg, rather than studying transvalvular pressure correlated to
mechanical stress. Also, Xing compared the aortic valve’s biological response
between pressure levels of 80-120mmHg, 120-160mmHg, and 150-190mmHg,
all of which had a 40mmHg difference in pressure.

116

To elucidate the effects of

transvalvular pressure with increasing amplitudes, a cyclic pressure bioreactor
will be created.

Design Requirements
To create a bioreactor that adequately mimics the dynamic transvalvular
pressure levels across the aortic valve, the system must cycle between at least
60 - 80mmHg for normotensive conditions, 60 - 90mmHg for Stage I
hypertension, and 60 - 100mmHg for Stage II hypertension.

The bioreactor

should cycle at a frequency of 1Hz, which correlates with a heart rate of 60 bpm.
At this frequency, the pressure should gradually increase to the target pressure
for approximately 0.6 seconds to simulate the aortic valve being closed during
diastole; the pressure should then drop to atmospheric pressure for 0.4 seconds
to simulate the aortic valve being open in systole with no pressure across the
leaflet, and repeat. The culture media contains additives and growth factors to
supply nutrients to the samples. To ensure proper gas exchange and maintain
ideal pH levels in the media, the bioreactor must sustain 100% humidity with 5%
CO2.

117

Also, the bioreactor must be able to fit within a standard incubator at
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37˚C to keep samples at normal core body temperature. Finally, the bioreactor
must be able to be sterilized to prevent tissue contamination and have a user
friendly interface for consistent and accurate operation.

System Overview
The system consisted of a chamber in which to place samples and
produce cyclic pressure, solenoid valves (McMaster-Carr, 4868K11) to control
the timing of the pressure cycle, and a computer to control electrical devices.
The pressure was monitored using a pressure transducer (Omega Engineering,
Inc., PX302-200GV) connected to the front of the chamber, and the signal was
conditioned using a load cell conditioner (Encore Electronics, Inc., Model 4025101). To produce a 5% CO2 environment within the chamber and control the
amount of pressure added to the system, the air supply solenoid valve was
connected to a ten gallon air tank containing 5% CO2 and a pressure regulator.
Also, to prevent backflow of pressure, the air supply valve was connected to a
bronze spring-loaded ball check valve (McMaster-Carr, 47715K41).

The

computer controlled the electrical devices via a data acquisition (DAQ) module
(Measurement Devices, PMD1608) and custom written software (LABView,
National Instruments).

31

Materials

Pressure Chamber Materials
A scratch resistant acrylic cylinder (McMaster-Carr, 8486K937) was used
to build the chamber of the bioreactor, which allowed the researcher to observe
the samples during testing. The cylinder had an outer diameter (OD) of 6”, an
inner diameter (ID) of 5.5”, and was 10” in length. The aluminum end plates
were 1” thick and had a 0.5” pilot with a 5.5” diameter that fitted tightly inside the
acrylic cylinder. The front end plate had a ¼” national pipe thread (NPT) hole
through the center of the plate, so the pressure transducer could read the
pressure from inside the chamber and send the information to the computer via
the DAQ module. The rear end plate had two ¼” NPT holes, one through the
center of the plate for the exhaust solenoid valve, and the other 2” above center
for the air supply solenoid valve. The rubber diaphragm within the solenoid valve
blocked the flow of air until electrically stimulated, as illustrated in Figure 9. Only
a 1 psi pressure differential was required to raise the lightweight, viton
diaphragm, which made the valve more energy efficient than most valves.
Diaphragm pilot-operated solenoid valves have a higher flow rate than both
direct-acting and piston pilot-operated valves, which made them an ideal choice
for rapid pressure influx and exhaust.
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Figure 9: Schematic of operation of normally-closed viton diaphragm solenoid
valve
(mcmaster.com)

A ten gallon air tank with 5% CO2 was connected to the air supply
solenoid valve via pressure regulator to create a pressurized environment
suitable for tissue culture. To prevent loss of pressure, the pilot of the rear end
plate had a 0.125” grove fitted with a 70 Duro o-ring (Hercules, 252) with a 5.5”
OD and a 5.25” ID to create a tight seal between the pilot and the acrylic cylinder,
thus making the plate difficult to remove. Nitrile was placed around the pilot on
the front plate, so it could be easily added and removed between experiments
without disrupting the samples. The two end plates were held together by four
threaded rods in each corner, tightened with nuts. The SolidWorks drawings of
the pressure chamber used in the system can be seen in APPENDIX A, whereas
actual pictures of the bioreactor are found in APPENDIX B. A ¼” thick aluminum
plate was used within the chamber to provide a flat surface within the cylinder on
which to rest the samples. The plate was 4.5” x 8” and had an area large enough
33

to support up to four 4” x 6” sample plates used in testing. A water reservoir was
also placed on top of the sample plate to create a 100% humidity environment
within the system.

A dissected side view of the pressure chamber, which

illustrates where the sample plate is located within the cylinder, can also be
found in APPENDIX A. Total volume of the chamber used to hold pressure,
excluding the volume of the pilots and sample plate, was 846.8 in³.

Electrical Devices Used
The pressure transducer was connected to the Analog In port 0 of the
DAQ module via BNC coaxial cables (RG-58, 50Ω) so LabVIEW could create a
continuous pressure versus time graph during testing and record the pressure. A
graph of the signaling of the air supply solenoid valve was produced by
connecting a wire from the air supply valve to the Analog In port 1, thus ensuring
the experimenter that the valves were signaled properly.

A 220Ω resistor,

transistor, and relay were connected in series, respectively, and were used to
control the activation of the solenoid valves. The air supply and exhaust solenoid
valves were connected to the DAQ module in Digital Out ports 0 and 1,
respectively. While the valve was uncharged, there was no current across the
resistor and the transistor was automatically grounded.

However, when the

computer sent a signal across the resistor to turn on the valve, immediately
thereafter the transistor connected the circuit, and the signal ran through the
relay. A three-pronged electrical extension cord was used to power the relay,
and was connected to the solenoid valves and relays as shown in APPENDIX C.
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The computer sent a 5V signal to turn on the relay via DC current and activated
the valve to remain open for the specified amount of time. A complete schematic
drawing of the electrical devices is shown in APPENDIX C.

Procedure Used to Run Bioreactor
Prior to experimentation, the bioreactor was sterilized with a 70% ethanol
solution.

The LabVIEW user interface had a switch marked “TEST” which

allowed the user to test each valve prior to experimentation to ensure proper
function and signaling from the computer. The LabVIEW interface prompted the
user to provide the amount of time the system cycled in diastole and systole, 0.6s
and 0.4s respectively, which controlled the timing of the valves when switched to
“RUN”. LabVIEW used this information to properly signal the air supplier and
exhaust solenoid valves. The program could allow researchers to not only test
normal physiological heart rate, but also varying pathological heart rates. The
user was also prompted to choose a sampling rate, which told the computer how
many pressure and signal readings to record per second.

The maximum

sampling rate of the pressure transducer used for the bioreactor was 10 samples
per second. Also, the computer asked the user for a Microsoft Excel file in which
to store the time, pressure, and signal readings, so the researcher was able to
review the pressure readings and ensure there was no drop in pressure or
improper signaling during testing. LabVIEW then created a signal and pressure
versus time graph, a waveform showing when the air supply valve was turned on
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and off, as well as a saw tooth waveform mimicking transvalvular pressure during
the cardiac cycle.

Sterility Tests
Prior to experimentation, the bioreactor was sterilized using a 70% ethanol
solution. Using sterile technique, the samples were placed inside the chamber,
which was then sealed to create an air-tight environment for testing. The pH and
absorbance of the medium involved in this study was compared prior to and after
11 hr of experimentation using a pH meter and spectrophotometer at 365nm,
respectively. A significant increase in medium pH or absorbance was considered
to imply the bioreactor had microbial growth or contamination, hence regarded as
a non-sterile environment for testing.

Results
The sterility tests measured by medium pH and absorbance indicated no
significant change occurred after 11hr of culture. The pH of the medium prior to
and after experimentation was 7.4, indicating no change in medium pH. The
media absorbance prior to testing was 0.5304±0.0099, whereas the absorbance
following testing was 0.5652±0.0296 (p>0.05; paired t-test), indicating no
microbial contamination; therefore, cleaning the sample surface of the bioreactor
with a 70% ethanol solution was suitable for container sterilization. In addition,
the ten gallon air tank containing 5% CO2 balanced with air allowed for 10.7 ±
0.205 hr of experimentation. Also noted, the temperature of the media after an
36

hour of experimentation dropped from 37˚C to 34.7˚C. The pressure chamber
met all of the system requirements of a cyclic pressure bioreactor for aortic valve
study.

The chamber (1) fit into a standard humidified incubator at 37˚C, (2)

perfused air with 5% CO2 to maintain pH and efficient gas exchange, (3)
maintained sterility throughout testing, and (4) cycled between diastolic
transvalvular pressure levels for physiological and pathological conditions. Figure
10 shows the simulation of the pressure levels used during valvular testing.

37

Normotensive

Pressure (mmHg)

A

100

80

Pressure

60

40

20

0

1

2

3

Seconds

Time (s)

Stage I Hypertension

Pressure (mmHg)

B

100

80

Pressure

60

40

20

0

1

2

3

Seconds

Time (s)

Stage II Hypertension

Pressure (mmHg)

C

100

80

Pressure

60

40

20

0

1

2

3

Seconds

Time (s)

Figure 10: Graph of pressure simulation within bioreactor at (A) normotensive,
(B) Stage I hypertensive, and (C) Stage II hypertensive conditions
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Discussion
The bioreactor created for this study met all of the functional requirements
and was successful in overcoming the limitations of the bioreactor previously
used within this research group. The previous pressure system consisted of a
stainless steel chamber with a 6.5” OD and 6” ID, and used a pneumatic cylinder
controlled by a waveform generator. Since the bioreactor was made of stainless
steel, it was extremely heavy, difficult to maneuver, and lacked transparency,
which prevented sample observation during testing.

In contrast, the current

design was made of an acrylic cylinder and aluminum plates, which were of
moderate weight, easily maneuvered, and transparent.

The area allotted for

testing in the previous bioreactor only allowed for two sample plates to be tested
simultaneously, whereas the current model easily accommodated four sample
plates at one time. Regarding functional requirements, the previous design was
limited by the magnitude and frequency of the waveform generated, due to the
incompressibility of air and lack of utilization of an exhaust valve. Without a valve
to allow a quick exhaust of pressure, the air used to produce the pressure had no
escape besides what was removed on the backstroke of the cylinder. For this
reason, higher pressure levels that required more air be added to the system, in
turn required more time to allow the pressure to drop, thus reducing the
frequency.

The current design, however, utilized an exhaust valve and was

therefore able to reach desired pressure magnitudes without affecting the
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frequency of the waveform.

Overall, the current design is superior to the

alternative in performance and convenience.
The bioreactor successfully exposed aortic valve leaflets to cyclic
transvalvular pressure with respect to diastole of the cardiac cycle; however, the
experiment was limited by the amount of time each experiment can be run.
Cellular differentiation into different phenotypes as a result of mechanical stress
may require more than ten hours of exposure to cyclic pressure; therefore, it is
important for the bioreactor to be capable of testing for extended periods of time.
To overcome this limitation, multiple air tanks can be connected to the bioreactor
for extended use, or possibly, an air return system can be created to constantly
cycle the exhaust air back into the chamber for continuous use. The latter option
may result in a loss of CO2 due to tissue gas exchange; therefore, experimenters
should be aware of this issue.
Also, it was important to note that the 2.3˚C drop in media temperature
was possibly due to the rapid influx of air mixture from a room temperature air
tank. The decreased media temperature may have little to no biological side
effects; however, to overcome this potential limitation a small heater can be used
to maintain media temperature by warming the aluminum sample plate on which
the samples rest.

This design alteration will require further investigation to

prevent overheating the media and should also utilize a temperature regulator to
maintain a consistent sample plate temperature, and as a result, media
temperature.
40

Aortic valve disease has only been associated with high diastolic
pressure; however, if both systolic and diastolic transvalvular pressure are to be
simulated (requiring the pressure to drop to zero rather than 40mmHg), a
vacuum pump and reservoir could possibly be connected to the exhaust solenoid
valve. The vacuum pump could be set to remove a fixed amount of pressure so
when the exhaust valve opens, the amount of air required to completely drop the
pressure from the set pressure level would be drawn into the vacuum reservoir.
The removal of the pressure would create a 0mmHg environment synonymous
with systolic transvalvular pressure. Conversely, when the exhaust valve closes,
the vacuum will no longer affect the chamber and will allow the pressure to
increase via pressurized air. This design, however, has not been tested and will
require further investigation.
In addition to testing aortic valves at varying pressures, it may be prudent
to study the effects of varying frequencies as well. For example, the effects of
changes in heart rate before, during, and after surgery could elucidate changes
in protein expression within the valve, and possibly explain why postoperative
arrhythmias occur in up to 20% of patients.

118-121

The LabVIEW program used

for this bioreactor allows the experimenter to choose the length of time air enters
and leaves the chamber; therefore, the frequency of the cycle can easily be
adjusted. The bioreactor allows for a maximum frequency of 1.5Hz (90bpm) due
to the amount of time required to exhaust the pressure from the system. As seen
in the results, a major pressure decrease occurred in the first 0.2s after exhaust
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valve activation, then gradually declined to the residual pressure for the
remaining 0.2s of exhaust.

The average pressure drop in the initial 0.2s of

exhaust was 45.8 ± 0.34mmHg, measured over 20 pressure cycles. Given that
testing Stage II hypertensive conditions only requires cycling pressure between
at least 60-100mmHg, a frequency of 1.5Hz allows 0.22s for exhaust, which is
ample time to drop 40mmHg of pressure. If a vacuum pump is attached to the
exhaust valve, it could facilitate a faster drop in pressure and would allow higher
frequency testing.

The minimum frequency of the bioreactor is not limited,

however, because the pressure regulator could allow slow influx of air and the
exhaust valve would have sufficient time to drop the pressure within the reactor.
To completely reduce the pressure from 100mmHg to 0mmHg requires
1.20±0.04s, reported from data analysis of 20 pressure cycles. Since the amount
of time the aortic valve is closed is approximately 2/3 of the cardiac cycle, the
influx of air into the pressure chamber would require 2.4s to create the same
balance of valve opening and closing experienced in physiological conditions. As
a result, a frequency of 0.28Hz would be used for testing the effects of both
systolic

and

diastolic

transvalvular

pressure

levels

on

aortic

valve

mechanobiology. Besides using a vacuum pump to increase the frequency and
closer mimic physiological conditions, an exhaust valve with a larger diameter
can be used to drop the pressure within the bioreactor more quickly. Currently,
the 3/8” diameter exhaust solenoid valve has a flow rate of 3.3 gallons per minute
(at 60˚F, specific gravity of 1); whereas, an exhaust valve with a 2” diameter has
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a flow rate of 28.0 gallons per minute. A larger diameter solenoid valve is more
cost effective than using a vacuum pump to increase bioreactor frequency,
however may not be able to drop the pressure completely to zero within
physiological range and should therefore be investigated further.
In conclusion, a sterile culture system has been constructed to allow study
of porcine aortic heart valve mechanobiology ex vivo. The pressure within the
bioreactor cycled between diastolic transvalvular pressure levels for physiological
and pathological conditions. To meet system requirements, the bioreactor was
compact and could therefore be contained within a humidified incubator to
maintain tissue temperature at 37˚C. An air tank containing 5% CO2 allowed gas
exchange to sustain a pH of 7.4 within the culture medium. Furthermore, the
pressure magnitude and frequency were controlled independently, allowing a
wide range of conditions to be studied.
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CHAPTER III
PRELIMINARY STUDY OF α/β-MYOSIN EXPRESSION

Introduction
Myosin heavy chain isoforms have been used to study smooth muscle cell
differentiation, as well as the cellular mechanisms of atherosclerosis.

122

Since

aortic valve disease is associated with atherosclerosis and interstitial cell
differentiation into smooth muscle cells, it is prudent to study the expression of
myosin within the aortic valve. As previously stated, three forms of myosin heavy
chain exist:

(1) α-MHC, (2) α/β-MHC, and (3) β-MHC.

Alpha- forms are

characterized as fast-twitch muscle fibers, whereas beta- forms are classified as
slow-twitch muscle fibers. The α/β-MHC show characteristics of both α- and βMHC, and are therefore considered the transdifferentiated form of myosin.
Interstitial cells that have differentiated into smooth muscle cells in response to
mechanical stimulation or injury express both α- and α/β- myosin heavy chain;
however, myosin within valvular endothelial cells has yet to be classified and
requires further investigation.

9

Previous studies have shown that hemodynamic

stimuli affect MHC gene expression; therefore, increased cyclic pressure may
cause amplification of myosin expression indicating a higher degree of fibroblast
differentiation, thus valvular remodeling. This study will examine the effects of
44

cyclic transvalvular pressure on cellular differentiation via α/β-myosin heavy chain
expression in porcine aortic heart valve leaflets. 123

Methods
Aortic valve leaflets were extracted from adult pigs within 10 min of
slaughter at a local abattoir (Sansing Meat Service, Maben, MS, USA). Five
aortic valve leaflets were fixed in 10% formalin (Fisher Scientific) immediately
following excision to serve as a control group. Leaflets used in testing were
placed in Dulbecco’s phosphate-buffered saline (PBS; Sigma) and transported to
the laboratory. Upon arrival, the leaflets were placed in 6-well plates with 5mL of
Dulbecco’s Modified Eagle Medium (DMEM; Sigma) supplemented with 1% Antibiotic/Anti-mycotic solution (ABAM; Sigma) and 10% fetal bovine serum (FBS;
Mediatech Inc.). Samples were then placed in a humidified incubator for 24
hours with 5% CO2 to allow the leaflets to adapt to the culture media before
experimentation. The protocol for leaflet extraction and culture can be found in
APPENDIX E. Five leaflet samples were fixed after 24 hours of incubation to
serve as secondary controls. Two hours prior to cyclic pressure experimentation,
the bioreactor was placed within the humidified incubator to allow temperature
stabilization within the testing chamber.

Five leaflets were place inside the

bioreactor and programmed to cycle from 40 – 80mmHg, simulating
normotensive transvalvular pressure. The same process was repeated at 40 –
90mmHg to test Stage I hypertensive conditions, and 40 – 100mmHg for Stage II
hypertensive conditions.

Each experimental run was tested under cyclic
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conditions for approximately 10hr, after which the samples were placed in a 10%
formalin fixative solution. After fixation, the samples were embedded in paraffin
and immunohistochemistry was performed to investigate changes in the cell
phenotype due to increasing cyclic pressure with regards to α/β-MHC (GeneTex,
Inc., GTX20015). The protocol used for antibody staining can also be found in
APPENDIX E. Heat-induced epitope retrieval was used to produce markedly,
improved antigen staining and also helped overcome false negative staining of
over-fixed tissue. Prior to heat exposure, the slides were submerged in a 10x
Target Retrieval solution (DAKO Corp., 51699) diluted to a 1:9 ratio using
distilled water. The slides were then placed inside a steamer for 30 minutes for
previously described epitope retrieval, then rinsed in distilled water and placed in
TRIS Buffer Saline (DAKO Corp., 5196830) until immunohistochemistry was to
be performed. The primary antibody, α/β-MHC, was optimized to a 1:800 dilution
and utilized antibody diluent (DAKO Corp., 5080983).

Secondary antibodies,

biotinylated link (yellow) and streptaradin horse reddish peroxidase (red) (LSAB2
System, DAKO Corp., K067589) were used to bind to the primary antibody and
increase the expression of the stain.

In

addition,

diaminobenzidine

tetrahydrochloride (DAB) (DAKO Corp., K346689) was used to form a brown
stain indicating positive expression of the α/β-MHC antigen in the end-product.
Furthermore, hydrogen peroxidase was used to block tissue endogenous
peroxidase activity and IgGI mouse (DAKO Corp., X0931) was used for a
negative control. The final step in the immunohistochemistry procedure involved
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counterstaining the slides.

Hematoxylin solution (Sigma-Aldrich, GHS332-1L)

was used to stain the nucleus of the cells blue and a 0.3% ammonia water
solution (1.5mL of ammonium hydroxide with 500mL of distilled water) tinted the
slides a bluish color.

Results
The results showed a random distribution of interstitial cells throughout the
leaflet, and a positively stained endothelium that slowly detached and lost protein
expression over time. Figure 11 shows an aortic valve leaflet fixed immediately
after excision with an intact arterial endothelium stained heavily for α/β-MHC.
The same leaflets also stained positive for myosin sporadically within the
subendothelial layer, as shown in Figure 12.

After 24 hours of culture, the

endothelial layer began to detach, however continued to stain positive for α/βMHC, as did a few smooth muscle cells in close proximity to the endothelium,
seen in Figure 13.

The five leaflets placed in the pressure chamber at

normotensive and Stage I hypertensive conditions showed no myosin staining
except occasionally at the site of extraction, displayed in Figure 14 and Figure 15.
Leaflets exposed to Stage II hypertensive pressure levels showed no α/β-MHC
staining except for one area located on the fibrosal endothelium, seen in Figure
16.
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Figure 11: Immunohistochemistry of α/β-myosin heavy chain of leaflet fixed
immediately after excision (A) 10x (B) 40x (focused on endothelium).
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Figure 12: Immunohistochemistry of α/β-myosin heavy chain of leaflet fixed
immediately after excision (A) 10x (B) 40x (focused on spongiosa
layer).
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Figure 13: Immunohistochemistry of α/β-Myosin heavy chain after 24 hours in
media (A) 10x (B) 40x (focused on fibrosal endothelium and
spongiosa)
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Figure 14: Immunohistochemistry of α/β-Myosin heavy chain exposed to 4080mmHg cyclic pressure (A) 10x (B) 40x (focused on site of excision).
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Figure 15: Immunohistochemistry of α/β-Myosin heavy chain exposed to 4090mmHg cyclic pressure (A) 10x (B) 40x (focused on site of excision).
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Figure 16: Immunohistochemistry of α/β-Myosin heavy chain exposed to 40100mmHg cyclic pressure (A) 10x (B) 40x (focused on fibrosal
endothelium).
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Discussion
This study showed that α/β-myosin heavy chain is present in the arterial
endothelial layer, and in smooth muscle cells within the subendothelial space of
porcine aortic valves. As discussed earlier, the presence of smooth muscle cells
indicates that the valve is undergoing remodeling. When the mechanosensitive
endothelial layer recognizes an alteration in hemodynamics, it signals the
interstitial cells to repair or remodel the extracellular matrix accordingly. The
quiescent

fibroblast

population

of

interstitial

cells

differentiates

into

myofibroblasts, and if necessary, further differentiates into smooth muscle cells.
The actual functions of the three phenotypes within the aortic valve are currently
unknown but are under investigation.
After 24 hours of incubation the endothelial layer begins to detach, and
myosin expression tends to decrease. Loss of the endothelial layer may be due
to insufficient mechanical stimulation required for cellular function. Metzler et al.
showed that 0-10% cyclic strain maintains the integrity of the valvular endothelial
monolayer without inducing a pro-inflammatory response, indicating a strain
range near that of physiological conditions; therefore, cyclic strain may be
required to keep the endothelial layer intact.
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Furthermore, normotensive and

Stage I hypertensive conditions showed no myosin on the slowly denuding
endothelium, except sporadically at the sites of extraction. One leaflet stimulated
by Stage II hypertensive conditions stained positive for α/β-MHC on a single node
of endothelial and subendothelial cells; however, no other myosin was found.
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The node found on a Stage II hypertensive leaflet was discovered near a
penetration site, possibly caused by tweezers during extraction. The subsequent
damage to the endothelium and extracellular matrix was again possibly due to
the high mechanical stress induced by the tweezers. The temporal limitations
due to the single ten gallon gas tank setup, as previously described, may have
contributed to the observed lack of cellular differentiation. Cellular response to
mechanical stimuli is often characterized following up to 72 hours of exposure, to
meet this time demand would require a multiple stage tank system or gas return
mechanism.
Since the majority of α/β-MHC expression was found on the endothelial
layer, this indicates the importance of keeping the endothelium intact. Additional
studies of myosin heavy chain expression within the aortic valve may involve the
creation of a biaxial cyclic strain device to maintain an intact endothelial layer.
The biaxial strain device should be sterile, noncorrosive, and able to fit within the
specifications of the pressure chamber. Also, additional programming would be
required to synchronize cyclic strain with cyclic pressure at adjustable heart
rates. If created, numerous studies could be performed involving variations of
pressure, cyclic strain, and heart rate.
As mentioned earlier, the developing heart initially expresses only β-MHC
and eventually converts completely to α-MHC when fully developed, with α/βMHC as the transitional form.

47,49,50

When the mechanical environment in the

heart becomes unstable, myosin reverts to its embryonic form, as shown by no α55

MHC expression at end-stage heart failure.
within the valve has been understudied.
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To date, the expression of myosin

An interesting study would be to

investigate what forms of myosin are expressed during valvulogenesis
(assumedly β-MHC), and compare the expression of each of the three forms of
MHC in mature leaflets exposed to physiological and pathological conditions.
With this study, investigators could discover whether or not the valve reverts to
its embryonic form as a result of changes in mechanical stimuli similar to the
cardiomyocytes of the heart.
Possible evidence of valvular redifferentiation to the embryonic state is the
deposition of calcium in diseased valves.

During valvulogenesis, bone

morphogenic protein (BMP) is among many molecules involved in epithelial
mesenchymal transformation.

125,126

BMP-2 induces the expression of periostin,

responsible for regulating collagen I fibrillogenesis and mediating matrix
maturation.

19,22,127

The exact pathways involved in valvulogenesis pertaining to

BMP and periostin expression are currently under investigation; however,
alteration of the valve’s mechanical and biochemical environment may reverse
and disrupt these pathways, causing bone (rather than collagen) to form within
the valve. Calcium deposits typically form at bending sites, synonymous with
sites of initial embryonic cushion formation. Additionally, BMPs are known to be
involved in the inflammatory response, which further implicates their role in valve
calcification.
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In conclusion, α/β-MHC was expressed in porcine aortic valve leaflets;
however, due to the loss of endothelium, myosin expression was reduced to sites
of injury and showed no significant change with increasing cyclic pressure. A
biaxial strain device may be employed to maintain the suitable mechanical force
required to keep the endothelium intact. Further study is necessary to elucidate
the biochemical pathways involved in differentiation and possible redifferentiation
of myosin within the aortic valve.

Summary
A cyclic pressure bioreactor was created to compare the α/β-myosin heavy
chain expression of porcine aortic heart valves between physiological and
pathological conditions. The bioreactor was successful in meeting all system
requirements and was therefore able to create a suitable environment for
subsequent testing.

Immunohistochemistry staining showed that myosin was

expressed on the fibrosal endothelium and also illuminated smooth muscle cells
within the subendothelial space.

Cyclic pressure, however, was unable to

maintain the endothelial layer, and myosin expression diminished over time.
Leaflets tested within the bioreactor expressed myosin only at areas of high
shear stress, such as sites of excision or tweezer penetration.
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APPENDIX A
SOLIDWORKS DRAWINGS OF BIOREACTOR
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Isometric View of Bioreactor with Material Properties
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72
Dimensions of Front End Plate
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Dimensions of Rear End Plate
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Dimensions of Acrylic Cylinder
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Dimensions of Sample Plate
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Dissected Side View of Bioreactor

Front View of Bioreactor

Top View of Bioreactor
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APPENDIX B
ACTUAL PHOTOGRAPHS OF PRESSURE CHAMBER SYSTEM
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Bioreactor within Incubator

Top View of Bioreactor with Circuit Board
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APPENDIX C
SCHEMATIC DRAWING OF ELECTRICAL CIRCUITRY
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APPENDIX D
LABVIEW USER INTERFACE
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APPENDIX E
PROTOCOLS
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Aortic Valve Leaflet Extraction and Culture
1. Extract aortic leaflets from annulus.
2. Place leaflets in Dulbecco’s phosphate-buffer saline (PBS; Sigma, St. Louis,
MO, USA).
3. Place leaflets in 6 well plates with 5 ml of media in each well.
Media:
Dulbecco’s Modified Eagle Medium (DMEM; Sigma)
10% fetal bovine serum (Mediatech Inc., Herndon, VA, USA)
1% Anti-biotic/Anti-mycotic solution (Sigma)
4. Place leaflets in media in humidified incubator at 37˚C with 5% CO2 for 24
hours.
5. Leaflets are prepared for pressurization.
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Immunohistochemisty Protocol for TRS/Proteinase K Pretreatments
1. Prepare worksheet - List antibodies (Ab), number of slides for each with
dilutions, pretreatments and reagent dispense locations and drop zones.
2. Program computer.
3. Prepare all reagents – Ab dilutions (α/β-myosin 1:800), blocking reagents,
secondary and tertiary reagents, substrate and counterstain.
4. Number slides and label with Accession number, treatment
identification and date. Use pencil.
5. Bake slides for 20 minutes at 60˚C.
6. Verify which slides require pretreatment with steam/TRS.
7. Set up steamer by filling bottom 2/3 full with dH2O.
8. Fill slide container with appropriate amount of 1X TRS (approx. 200 ml).
9. Preheat steamer for 20 minutes.
10. Deparaffinization schedule:
(Note: Deparaffinize slides to be pretreated with TRS first, then process
others.)
1. Xylene (used ≤ 3x) 10 min.
2. Xylene (fresh) 10 min.
3. 100% EtOH (used ≤ 3x) 10 dips
4. 100% EtOH (fresh) 10 dips
5. 70% EtOH (used ≤ 3x) 10 dips
6. 70% EtOH (fresh) 10 dips
7. Rinse well with dH2O
11. Place slides in TBSTw for at least 5 min. (can be held o/n)
12. Place appropriate slides in steamer for 20 min. (hold others in
TBSTw). When finished, let slides cool to room temp before putting in
TBSTw for at least 5 min.
13. While steaming slides, saturate the autostainer with heated dH2O.
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14. Load slides.
15. Prime pumps.
16. Start run. Observe beginning of run to assure no problems.
17. Save run log.
18. Remove slides and rinse with dH2O.
19. Load slides.
20. Prime pumps.
21. Start run. Observe beginning of run to assure no problems.
22. Save run log.
23. Remove slides and rinse with dH2O.
24. Put slides in 100% EtOH for approximately 3 min and then into ClearRite.
25. Cover slip with Permount.
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